On 5 March 2009, Sosei Group Corporation announced that it has sold its intellectual property portfolio of patents covering chronotherapeutic drug formulations to the Swiss-German drug development company, Nitec Pharma AG.
Nitec is developing a chronotherapeutic formulation of the corticosteroid, prednisalone, and wishes to consolidate its own patent portfolio in this therapy area. The Sosei IP provides coverage for a range of dose forms not protected directly by Nitec’s patents.